Item 4 — Purpose of Transaction
Item 4 of the Schedule 13D is hereby amended and restated in its entirety as follows: On July 15, 2026, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to satisfaction or waiver of the conditions therein, Merger Sub will merge with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Parent. On July 15, 2026, in connection with the execution of the Merger Agreement, Apeiron and Christian Angermeyer entered into separate Voting and Support Agreements (the "Support Agreements") with Parent. The Support Agreements provide that, among other things, each of Apeiron and Christian Angermeyer has agreed (i) to vote all of the shares of common stock held by such stockholder in favor of the adoption of the Merger Agreement, subject to certain exceptions (including the valid termination of the Merger Agreement), (ii) not to transfer such shares of common stock, and (iii) to certain other restrictions on its ability to take actions with respect to the Company and its shares of common stock. The foregoing descriptions of the Support Agreements does not purport to be complete and is qualified in its entirety by the full text of the form of Support Agreement, a copy of which is filed as Exhibit 99.1 to this Amendment No. 4 and is incorporated into this Item 4 by reference. A copy of the form of Support Agreement and the above description of the Support Agreements have been included to provide investors with information regarding the terms of the Support Agreements. They are not intended to provide any other factual information about the parties to the Support Agreements or their respective subsidiaries or affiliates. The representations, warranties and covenants contained in the Support Agreements were made only for the purposes of the Support Agreements and as of specific dates, are solely for the benefit of the parties to the Support Agreements, may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures made for the purposes of allocating contractual risk between the parties to the Support Agreements instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Investors are not third-party beneficiaries under the Support Agreements and should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the parties thereto or any of their respective subsidiaries or affiliates. Moreover, information concerning the subject matter of representations and warranties may change after the date of the Support Agreements, which subsequent information may or may not be fully reflected in the Reporting Persons', the Issuer's or Parent's public disclosures.